These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9310483)

  • 1. An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers.
    Lindstrom AL; Erlandsen SL; Kersey JH; Pennell CA
    Blood; 1997 Sep; 90(6):2323-34. PubMed ID: 9310483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.
    Soler-Rodríguez AM; Ghetie MA; Oppenheimer-Marks N; Uhr JW; Vitetta ES
    Exp Cell Res; 1993 Jun; 206(2):227-34. PubMed ID: 8388800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage.
    Baluna R; Coleman E; Jones C; Ghetie V; Vitetta ES
    Exp Cell Res; 2000 Aug; 258(2):417-24. PubMed ID: 10896793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.
    Baluna R; Rizo J; Gordon BE; Ghetie V; Vitetta ES
    Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3957-62. PubMed ID: 10097145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a highly sensitive in vitro endothelial cell toxicity assay for evaluating ricin toxin A chain-based vaccines or therapeutics.
    Machesky NJ; Rusnak JM; Moore EH; Dorsey CB; Ward LA
    Toxicon; 2019 Sep; 167():152-161. PubMed ID: 31207351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in vivo model to study immunotoxin-induced vascular leak in human tissue.
    Baluna R; Vitetta ES
    J Immunother; 1999 Jan; 22(1):41-7. PubMed ID: 9924698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA; Carroll SF; Snover DC; Carlson GJ; Blazar BR
    Blood; 1991 Jan; 77(1):182-94. PubMed ID: 1984794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells.
    Baluna R; Ghetie V; Oppenheimer-Marks N; Vitetta ES
    Int J Immunopharmacol; 1996; 18(6-7):355-61. PubMed ID: 9024936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
    Liu XY; Pop LM; Schindler J; Vitetta ES
    MAbs; 2012; 4(1):57-68. PubMed ID: 22327430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies of ricin A-chain-induced vascular leak syndrome.
    Lindstrom AL; Pennell CA
    Methods Mol Biol; 2001; 166():125-35. PubMed ID: 11217363
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of a ricin vaccine candidate (RVEc) for human toxicity using an in vitro vascular leak assay.
    Porter A; Phillips G; Smith L; Erwin-Cohen R; Tammariello R; Hale M; DaSilva L
    Toxicon; 2011 Jul; 58(1):68-75. PubMed ID: 21616091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures.
    Chignola R; Anselmi C; Dalla Serra M; Franceschi A; Fracasso G; Pasti M; Chiesa E; Lord JM; Tridente G; Colombatti M
    J Biol Chem; 1995 Oct; 270(40):23345-51. PubMed ID: 7559491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.
    Manske JM; Buchsbaum DJ; Vallera DA
    J Immunol; 1989 Mar; 142(5):1755-66. PubMed ID: 2465347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adapting yeast as model to study ricin toxin a uptake and trafficking.
    Becker B; Schmitt MJ
    Toxins (Basel); 2011 Jul; 3(7):834-47. PubMed ID: 22069743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monocrotaline pyrrole interacts with actin and increases thrombin-mediated permeability in pulmonary artery endothelial cells.
    Wilson DW; Lamé MW; Dunston SK; Taylor DW; Segall HJ
    Toxicol Appl Pharmacol; 1998 Sep; 152(1):138-44. PubMed ID: 9772209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinations of low concentrations of cytokines and acute agonists synergize in increasing the permeability of endothelial monolayers.
    Beynon HL; Haskard DO; Davies KA; Haroutunian R; Walport MJ
    Clin Exp Immunol; 1993 Feb; 91(2):314-9. PubMed ID: 8428396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: assessment of LD50 and MTD of four ricin-based anti-cCLLa immunotoxins (ITs) in Balb/c mice.
    Faguet GB; Agee JF
    Leuk Lymphoma; 1997 May; 25(5-6):531-7. PubMed ID: 9250824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permeability of human endothelial monolayers: effect of vasoactive agonists and cAMP.
    Casnocha SA; Eskin SG; Hall ER; McIntire LV
    J Appl Physiol (1985); 1989 Nov; 67(5):1997-2005. PubMed ID: 2480947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of ricin toxin A chain in rats.
    Alipour M; Pucaj K; Smith MG; Suntres ZE
    Drug Chem Toxicol; 2013 Apr; 36(2):224-30. PubMed ID: 22947129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreases in levels of serum fibronectin predict the severity of vascular leak syndrome in patients treated with ricin A chain-containing immunotoxins.
    Baluna R; Sausville EA; Stone MJ; Stetler-Stevenson MA; Uhr JW; Vitetta ES
    Clin Cancer Res; 1996 Oct; 2(10):1705-12. PubMed ID: 9816120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.